Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 26:15:20406223241230180.
doi: 10.1177/20406223241230180. eCollection 2024.

Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea

Byung Soo Kim  1 , Dong Hyun Kim  2 , Bong Seok Shin  3 , Eun-So Lee  4 , Seong Jin Jo  5 , Chul Hwan Bang  6 , Yeojun Yun  7 , Yong Beom Choe  8   9
Affiliations

Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea

Byung Soo Kim et al. Ther Adv Chronic Dis. .

Abstract

Background: Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015.

Objectives: To assess the safety and effectiveness of secukinumab in patients with moderate to severe psoriasis in Korea.

Design: Multicenter, real-world, noninterventional study conducted over 6 years.

Methods: Adults with moderate to severe psoriasis were enrolled. Safety was assessed by evaluating adverse events (AEs), treatment-related AEs, and serious AEs (SAEs). Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, percentage of patients achieving PASI 75/90/100 and PASI ⩽2; at weeks 12 and 24.

Results: Overall, 829 and 542 patients were included in the safety and effectiveness sets, respectively. AEs, treatment-related AEs, and SAEs occurred in 29.0%, 9.5%, and 4.1% of patients, with incidence rates of 39.43, 12.98, and 5.59 per 100 patient years, respectively. The absolute PASI score decreased from 16.1 ± 7.1 (baseline) to 1.6 ± 2.4 (week 24), with a similar reduction in biologic-naïve (16.4 ± 7.3 to 1.5 ± 2.2) and biologic-experienced (14.8 ± 5.9 to 2.4 ± 3.2) groups. At week 24, PASI 75/90/100 was achieved by 95.1%, 62.4%, and 24.9% of patients. At week 24, PASI 75/90 were higher in biologic-naïve (96.6%/65.8%) than biologic-experienced patients (88.3%/48.6%), whereas PASI 100 was similar in both cohorts (24.1% and 28.6%). A similar trend in PASI ⩽ 2 was observed in both cohorts.

Conclusion: Secukinumab showed sustained effectiveness and favorable safety profile in adult patients with moderate to severe psoriasis in Korea.

Keywords: effectiveness; psoriasis; real-world evidence; safety; secukinumab.

PubMed Disclaimer

Conflict of interest statement

BSK served as a scientific adviser, a clinical study investigator, and/or a speaker for Abbvie, Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Galderma, GlaxoSmithKline, Green Cross, Janssen, Kyowa Hakko Kirin, LEO-Pharma, Novartis, Regeneron, Samsung, Sanofi, and UCB. SJJ reported receiving grants from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Green Cross Laboratories, Pfizer, and UCB and personal fees from AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals, LEO Pharma, Novartis, and Sanofi. CHB has served as an investigator in clinical trials sponsored by AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Janssen, Novartis, Pfizer, and UCB biopharma, and has received consultancy fees from AbbVie, Boehringer Ingelheim, Janssen, Kolon Pharma, Lilly, and Novartis, and fees for speaking from AbbVie, Janssen, Lilly, and Novartis. DHK served as a scientific adviser, a clinical study investigator, and/or a speaker for AbbVie, Bristol-Myers Squibb, Celltrion, Eli Lilly, Green Cross, Janssen, LEO-Pharma, Novartis, and UCB. E-SL received grants for clinical research from AbbVie, Inc., Bristol-Myers Squibb, Celgene Corporation, Cell Biotech, Lilly, Janssen Pharmaceuticals, Inc., and Servier; served as an advisor or consultant for AbbVie, Inc., Celgene Corporation, Galderma Korea, Janssen Pharmaceuticals, Inc., Lilly, and Novartis Pharmaceuticals Corporation. YY is an employee of Novartis Korea Ltd. BSS and YBC report no competing interests.

Figures

Figure 1.
Figure 1.
Distribution of the density of overall PASI scores at baseline, week 12, and week 24 in total patients (N = 829). PASI, Psoriasis Area and Severity Index.
Figure 2.
Figure 2.
Change in PASI over time. (a) Absolute PASI score. (b) Percentage change from baseline in PASI score. PASI, Psoriasis Area and Severity Index.
Figure 3.
Figure 3.
Percentage of patients achieving PASI 75, PASI 90, PASI 100, and percentage of patients who had PASI ⩽2 over time. PASI, Psoriasis Area and Severity Index.
See this image and copyright information in PMC

References

    1. Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet 2021; 397: 1301–1315. - PubMed
    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 2020; 323: 1945–1960. - PubMed
    1. Zhou X, Chen Y, Cui L, et al. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis 2022; 13: 81. - PMC - PubMed
    1. National Psoriasis Foundation. Psoriasis Statistics, https://www.psoriasis.org/psoriasis-statistics/ (accessed 14 October 2022).
    1. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377–385. - PubMed

LinkOut - more resources